Table 3.
Clinical Characteristics of Patients With Nonsquamous NSCLC Who Received ICIs
| Characteristics | All Patients | Responder | Nonresponder | pa |
|---|---|---|---|---|
| Total | 25 | 8 (32.0) | 17 (68.0) | |
| Age, median, y (range) | 63.2 (38.9–85.8) | 60.2 (45.5–80.5) | 63.9 (38.9–85.8) | 0.673b |
| Sex | 1.000 | |||
| Female | 4 | 1 (12.5) | 3 (17.6) | |
| Male | 21 | 7 (87.5) | 14 (82.4) | |
| Smoking status | 1.000 | |||
| Nonsmokers | 7 | 2 (25.0) | 5 (29.4) | |
| Smokers | 18 | 6 (75.0) | 12 (70.6) | |
| Tumor | 0.448 | |||
| Adenocarcinoma | 22 | 8 (100.0) | 14 (82.4) | |
| Pleomorphic or sarcomatoid | 1 | 0 (0.0) | 1 (5.9) | |
| NSCLC-NOS | 2 | 0 (0.0) | 2 (11.8) | |
| PD-L1 TPS, % | 0.225 | |||
| >50 | 12 | 5 (62.5) | 7 (41.2) | |
| 1–49 | 8 | 3 (37.5) | 5 (29.4) | |
| <1 | 5 | 0 (0.0) | 5 (29.4) | |
| Kras mutations | 0.030 | |||
| G12C | 13 | 7 (87.5) | 6 (35.3) | |
| Non-G12C | 12 | 1 (12.5) | 11 (64.7) | |
| ICIs | 0.548 | |||
| Pembrolizumab | 14 | 6 (75.0) | 8 (47.1) | |
| Nivolumab | 2 | 0 (0.0) | 2 (11.8) | |
| Atezolizumab | 5 | 1 (12.5) | 4 (23.5) | |
| Otherc | 4c | 1 (12.5) | 3 (17.6) | |
| Combination therapy | 1.000 | |||
| Combo | 5 | 2 (25.0) | 3 (17.6) | |
| Single use | 20 | 6 (75.0) | 14 (82.4) |
Note: Values are given in number (%) unless indicated otherwise.
ICI, immune checkpoint inhibitor; NOS, not otherwise specified; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
a
By Fisher’s exact test.
b
By Mann-Whitney U test.
c
One tremelimumab plus durvalumab, one tislelizumab (BGB-A317), and two spartalizumab (PDR001).